Literature DB >> 6703676

Hemodialysis elimination rates and clearance of gentamicin and tobramycin.

G R Matzke, C E Halstenson, W F Keane.   

Abstract

The apparent hemodialyzer elimination rate constant and clearance for gentamicin and tobramycin were determined during 100 routine hemodialysis treatments in 49 patients. Three different dialyzers (CDAK 3500, CF 1211, and CF 1511), which vary in membrane composition, surface area, and thickness, were evaluated. The elimination rate constant in each patient was calculated from the slope of the log serum concentration-time curves. Two different elimination rate constants for each patient were derived, one during hemodialysis (KT) and one off hemodialysis (K). The hemodialyzer elimination rate constant (KD) for each dialyzer was calculated as the difference between these two values. The hemodialyzer clearance (Cd) was calculated by multiplying the hemodialyzer elimination rate constant by the volume of distribution of the patient. The KDS of gentamicin and tobramycin by the three dialyzers were significantly different. The gentamicin KD of the CDAK 3500 was lower than the values of the CF 1211 and CF 1511 (0.086 versus 0.123 versus 0.131 h-1, respectively). The Cd of the CDAK 3500 for gentamicin was also significantly lower than that of the CF 1511. Although the CdS of tobramycin for the CF 1211 and CF 1511 were 24 and 43% greater than that for the CDAK 3500, these differences were not statistically significant. The KD and Cd of tobramycin were greater than those of gentamicin for all three dialyzers. These data demonstrate that commonly used hemodialyzers vary markedly with respect to their elimination and clearance characteristics of gentamicin and tobramycin. Clinically, these observations may be helpful in designing the correct dose of gentamicin and tobramycin to achieve maximum drug safety and efficacy in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703676      PMCID: PMC185450          DOI: 10.1128/AAC.25.1.128

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys.

Authors:  B A Halpren; S G Axline; N S Coplon; D M Brown
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Pharmacokinetics of gentamicin and kanamycin during hemodialysis.

Authors:  M Danish; R Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

4.  Rebound gentamicin levels after hemodialysis.

Authors:  L A Bauer
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

5.  Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.

Authors:  J C Péchère; R Dugal
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

Review 6.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

7.  Prediction of serum gentamicin concentrations in patients undergoing hemodialysis.

Authors:  D R Goetz; S Pancorbo; S Hoag; P Bloom
Journal:  Am J Hosp Pharm       Date:  1980-08

8.  Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics--part 4: aminoglycosides.

Authors:  M Barza; R T Scheife
Journal:  Am J Hosp Pharm       Date:  1977-07

9.  Gentamicin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure.

Authors:  L Létourneau-Saheb; L Lapierre; R Daigneault; M Prud'Homme; G St-Louis; G Serois
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

10.  Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.

Authors:  W R Lockwood; J D Bower
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

View more
  6 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients.

Authors:  Mohammed A Al-Homrany; Yacoub M Irshaid; Assem K El Sherif; Haider A Omar
Journal:  Int Urol Nephrol       Date:  2008-09-03       Impact factor: 2.370

3.  Isepamicin disposition in subjects with various degrees of renal function.

Authors:  C E Halstenson; J S Kelloway; M B Affrime; C C Lin; M A Teal; B E Shapiro; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.

Authors:  Kevin M Sowinski; Stephanie J Magner; Aroonrut Lucksiri; Meri K Scott; Richard J Hamburger; Bruce A Mueller
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

5.  Bayesian pharmacokinetics of gentamicin in a haemodialysis population.

Authors:  Lavern M Vercaigne; Robert E Ariano; James M Zacharias
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.